Penumbra, Inc. (PEN)
NYSE: PEN · Real-Time Price · USD
266.19
+1.58 (0.60%)
At close: Nov 7, 2025, 4:00 PM EST
266.19
0.00 (0.00%)
After-hours: Nov 7, 2025, 4:10 PM EST
Penumbra Employees
Penumbra had 4,500 employees as of December 31, 2024. The number of employees increased by 300 or 7.14% compared to the previous year.
Employees
4,500
Change (1Y)
300
Growth (1Y)
7.14%
Revenue / Employee
$296,400
Profits / Employee
$36,450
Market Cap
10.43B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4,500 | 300 | 7.14% |
| Dec 31, 2023 | 4,200 | 300 | 7.69% |
| Dec 31, 2022 | 3,900 | 100 | 2.63% |
| Dec 31, 2021 | 3,800 | 500 | 15.15% |
| Dec 31, 2020 | 3,300 | 600 | 22.22% |
| Dec 31, 2019 | 2,700 | 500 | 22.73% |
| Dec 31, 2018 | 2,200 | 500 | 29.41% |
| Dec 31, 2017 | 1,700 | 200 | 13.33% |
| Dec 31, 2016 | 1,500 | 400 | 36.36% |
| Dec 31, 2015 | 1,100 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PEN News
- 1 day ago - Penumbra, Inc. (PEN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Penumbra, Inc. Reports Third Quarter 2025 Financial Results - PRNewsWire
- 4 days ago - Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism - PRNewsWire
- 11 days ago - Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism - PRNewsWire
- 11 days ago - Penumbra, Inc. (PEN) Presents at Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025 - PRNewsWire
- 2 months ago - Penumbra, Inc. (PEN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile - PRNewsWire